These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 19280551

  • 1. Spiking expression of mu-crystallin mRNA during treatment with methimazole in patients with graves' hyperthyroidism.
    Suzuki S, Takei M, Nishio S, Inaba H, Sato A, Yamazaki M, Shinomiya K, Hashizume K.
    Horm Metab Res; 2009 Jul; 41(7):548-53. PubMed ID: 19280551
    [Abstract] [Full Text] [Related]

  • 2. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
    Roti E, Gardini E, Minelli R, Bianconi L, Salvi M, Gavaruzzi G, Braverman LE.
    J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
    [Abstract] [Full Text] [Related]

  • 3. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
    Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P.
    Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
    [Abstract] [Full Text] [Related]

  • 4. Correction of insulin resistance in methimazole-treated patients with Graves disease.
    Tene C, Zárate A, Basurto L, Islas S, Revilla C, Ochoa R, Galván R, Santos P.
    Rev Invest Clin; 2001 Oct; 53(6):531-5. PubMed ID: 11921526
    [Abstract] [Full Text] [Related]

  • 5. Treatment outcome of Graves' disease in Thai children.
    Somnuke PH, Pusuwan P, Likitmaskul S, Santiprabhob J, Sawathiparnich P.
    J Med Assoc Thai; 2007 Sep; 90(9):1815-20. PubMed ID: 17957924
    [Abstract] [Full Text] [Related]

  • 6. mu-crystallin, a NADPH-dependent T(3)-binding protein in cytosol.
    Suzuki S, Mori J, Hashizume K.
    Trends Endocrinol Metab; 2007 Sep; 18(7):286-9. PubMed ID: 17692531
    [Abstract] [Full Text] [Related]

  • 7. Antithyroid drug-induced immunomodulation in Graves' disease patients.
    Lechpammer M, Lukac J, Lechpammer S, Kusić Z.
    Acta Med Croatica; 2002 Sep; 56(1):21-6. PubMed ID: 12455450
    [Abstract] [Full Text] [Related]

  • 8. No association between Fas A/G polymorphism and therapeutic effects induced by methimazole treatment for Graves' disease in Northern Chinese.
    Li P, Li Q, Chen L, Sun Y, Zhang J.
    Pharmazie; 2008 Oct; 63(10):748-50. PubMed ID: 18972838
    [Abstract] [Full Text] [Related]

  • 9. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.
    Tsai WC, Pei D, Wang TF, Wu DA, Li JC, Wei CL, Lee CH, Chen SP, Kuo SW.
    Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819
    [Abstract] [Full Text] [Related]

  • 10. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
    Molnár I.
    Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
    [Abstract] [Full Text] [Related]

  • 11. Methimazole treatment in Graves' disease: behaviour of CD5+B lymphocytes and regulatory T cell subsets.
    Paggi A, Amoroso A, Ferri GM, Mariotti A, Pellegrino C, Afeltra A.
    Eur Rev Med Pharmacol Sci; 1998 Feb; 2(1):11-9. PubMed ID: 9825565
    [Abstract] [Full Text] [Related]

  • 12. Quantitative measurements for type 1 deiodinase messenger ribonucleic acid in human peripheral blood mononuclear cells: mechanism of the preferential increase of T3 in hyperthyroid Graves' disease.
    Nishikawa M, Toyoda N, Yonemoto T, Ogawa Y, Tabata S, Sakaguchi N, Tokoro T, Gondou A, Yoshimura M, Yoshikawa N, Inada M.
    Biochem Biophys Res Commun; 1998 Sep 29; 250(3):642-6. PubMed ID: 9784399
    [Abstract] [Full Text] [Related]

  • 13. The role of the IL-23/IL-17 axis in the pathogenesis of Graves' disease.
    Zheng L, Ye P, Liu C.
    Endocr J; 2013 Sep 29; 60(5):591-7. PubMed ID: 23327801
    [Abstract] [Full Text] [Related]

  • 14. Changes of serum cytokines in hyperthyroid Graves' disease patients at diagnosis and during methimazole treatment.
    Pedro AB, Romaldini JH, Takei K.
    Neuroimmunomodulation; 2011 Sep 29; 18(1):45-51. PubMed ID: 20628263
    [Abstract] [Full Text] [Related]

  • 15. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
    Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Barani L, Ferrannini E, Serio M.
    Clin Endocrinol (Oxf); 2006 Feb 29; 64(2):189-95. PubMed ID: 16430719
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of Graves' hyperthyroidism--prognostic factors for outcome.
    Alfadda A, Malabu UH, El-Desouki MI, Al-Rubeaan KA, Al-Ruhaily AD, Fouda MA, Al-Maatouq MA, Sulimani RA.
    Saudi Med J; 2007 Feb 29; 28(2):225-30. PubMed ID: 17268701
    [Abstract] [Full Text] [Related]

  • 18. Expression of very late antigen-4 and lymphocyte function-associated antigen-1 on peripheral blood lymphocytes from patients with graves disease.
    Bossowski A, Urban M, Stasiak-Barmuta A, Turowski D.
    Pediatr Res; 2002 Oct 29; 52(4):533-7. PubMed ID: 12357047
    [Abstract] [Full Text] [Related]

  • 19. CRYM mutations cause deafness through thyroid hormone binding properties in the fibrocytes of the cochlea.
    Oshima A, Suzuki S, Takumi Y, Hashizume K, Abe S, Usami S.
    J Med Genet; 2006 Jun 29; 43(6):e25. PubMed ID: 16740909
    [Abstract] [Full Text] [Related]

  • 20. The distribution of the major peripheral blood T, B and NK cell subsets does not predict the clinical outcome of Graves' disease patients after methimazole therapy.
    Corrales JJ, López A, Ciudad J, Orfao A.
    J Biol Regul Homeost Agents; 2000 Jun 29; 14(3):193-9. PubMed ID: 11037052
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.